BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 9819415)

  • 1. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
    Freedman DA; Levine AJ
    Mol Cell Biol; 1998 Dec; 18(12):7288-93. PubMed ID: 9819415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Xirodimas DP; Stephen CW; Lane DP
    Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.
    Yu ZK; Geyer RK; Maki CG
    Oncogene; 2000 Nov; 19(51):5892-7. PubMed ID: 11127820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
    Joseph TW; Zaika A; Moll UM
    FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MDM2 RING-finger domain is required to promote p53 nuclear export.
    Geyer RK; Yu ZK; Maki CG
    Nat Cell Biol; 2000 Sep; 2(9):569-73. PubMed ID: 10980696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.
    Laín S; Midgley C; Sparks A; Lane EB; Lane DP
    Exp Cell Res; 1999 May; 248(2):457-72. PubMed ID: 10222137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.
    Stewart D; Ghosh A; Matlashewski G
    J Virol; 2005 Jul; 79(14):8773-83. PubMed ID: 15994771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding.
    Inoue T; Geyer RK; Howard D; Yu ZK; Maki CG
    J Biol Chem; 2001 Nov; 276(48):45255-60. PubMed ID: 11572869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
    Traidej M; Chen L; Yu D; Agrawal S; Chen J
    Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of p53 in cervical carcinoma cells by small molecules.
    Hietanen S; Lain S; Krausz E; Blattner C; Lane DP
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8501-6. PubMed ID: 10900010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
    Tao W; Levine AJ
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3077-80. PubMed ID: 10077639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination.
    O'Keefe K; Li H; Zhang Y
    Mol Cell Biol; 2003 Sep; 23(18):6396-405. PubMed ID: 12944468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.
    Hengstermann A; Linares LK; Ciechanover A; Whitaker NJ; Scheffner M
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1218-23. PubMed ID: 11158620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
    Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
    Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein.
    Menéndez S; Higgins M; Berkson RG; Edling C; Lane DP; Laín S
    Br J Cancer; 2003 Feb; 88(4):636-43. PubMed ID: 12592381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function.
    Lu W; Pochampally R; Chen L; Traidej M; Wang Y; Chen J
    Oncogene; 2000 Jan; 19(2):232-40. PubMed ID: 10645001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage.
    Shirangi TR; Zaika A; Moll UM
    FASEB J; 2002 Mar; 16(3):420-2. PubMed ID: 11790725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination.
    Sionov RV; Coen S; Goldberg Z; Berger M; Bercovich B; Ben-Neriah Y; Ciechanover A; Haupt Y
    Mol Cell Biol; 2001 Sep; 21(17):5869-78. PubMed ID: 11486026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
    Camus S; Higgins M; Lane DP; Lain S
    FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF).
    Seavey SE; Holubar M; Saucedo LJ; Perry ME
    J Virol; 1999 Sep; 73(9):7590-8. PubMed ID: 10438849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.